Coronary heart disease (CHD) poses a major public health burden worldwide, with a complex etiology involving numerous environmental and genetic factors. To evaluate and estimate the CHD risk in patients, different risk scores have been developed, mainly based on classical risk factors. In the recent years, there has been a tremendous success of genome wide association studies (GWAS) in identifying variants affecting disease risk, e.g. variants associated with CHD risk currently including over 50 independent genetic loci [1, 2] . Typically, the effect sizes and the variance in CHD explained by genetic variants are modest.
This leads to the question of whether it is possible to improve individual risk estimates by the addition of genetic measures to current prediction tools and combine information of multiple variants, even with small effects, into a single genetic risk score (GRS).
So far, several studies have investigated the utility of a GRS in addition to established CHD risk algorithm, such as the European Heart Score or the Framingham Heart Study risk score for improved prediction [3] [4] [5] . Incorporating multiple variants into a GRS can be performed by either counting the number of risk alleles (unweighted GRS) or by multiplying the number of risk alleles by their effect sizes (weighted GRS). Subsequently, prediction improvement must be demonstrated in the established risk scores using standard metrics including discrimination, calibration, risk reclassification and, thereby, testing their potential clinical utility [6] .
In this issue of Clinical Chemistry and Laboratory Medicine, Beaney et al. [7] assessed the potential clinical utility of adding a GRS to the British risk score model QRISK2. The authors relied on a weighted 19-single nucleotide polymorphism (SNP) GRS that they previously found to be associated with CHD in a prospective British male cohort (Northwick Park Heart Study [NPHSII]) consisting of 3059 individuals [8] . In the current study, the authors modified the weights of this 19-SNP GRS based on the reported odds ratios from CARDIoGRAMplusC4D meta-analysis [9] . The combination of the British QRISK2 plus the updated 19-SNP GRS was identified to be well calibrated in NPHSII and to improve both discrimination and risk classification between CHD cases and controls as compared to QRISK2 alone. Furthermore, the addition of the GRS to the Framingham Risk Score [10] was poorly calibrated. The authors concluded that the combination of the updated 19-SNP GRS and QRISK2 would have clinical utility in the UK. Finally, to improve their GRS the 19-SNP GRS was modified by replacing five SNPs with weak CHD risk effects with seven new SNPs that showed strong associations in CARDIoGRAMplusC4D. These newly incorporated SNPs were de novo genotyped in NPHSII and subsequently, missing genotypes were imputed to increase the number of participants for the analyses. In combination with QRISK2, the "non-imputed" 21-SNP GRS was again well-calibrated and showed associations with lipids traits, and improved discrimination. However, when the imputed 21-SNP GRS was added to QRISK2 the combined score was poorly calibrated and showed no improvement in discrimination and reclassification.
Overall, this study adds further evidence that the inclusion of genetic information to established risk calculators could be of clinical relevance for CHD risk stratification. An obvious strength of genetic markers is that they do not change throughout life. However, several important hurdles such as the heterogeneity of the different ethnic and gender groups, the selection of genetic variants to be included in the GRS, and the technical challenges, remain to be discussed and to be further evaluated (Figure 1 ).
In the current publication, Beaney et al. [7] relied on a previously developed GRS, which replicated in a UK population, but did not replicate in two South Asian cohorts [8] . This discrepancy may result from a genetic heterogeneity between both populations, and population-specific GRSs may be needed in the future to ensure high predictive power. Additionally, not all SNPs from the original GRS could replicate in the large CARDIoGRAMplusC4D metaanalysis, whereas the updated (and imputed) 21-SNP GRS did not show improvement in risk prediction in the British cohort. Potential explanations for the fact that not all individual SNPs replicated in other cohorts could be different samples sizes and statistical power, different phenotype definition, or different cohort design.
Although accurate CHD risk prediction -specifically in middle-aged men, is needed to reduce the burden of disease more effectively [6] , it is widely known that sex and a positive family history are strong risk factors for developing CHD and that genetics might exert different effects in both sexes. The British NPHSII cohort used by Beaney et al. [7] to develop and test the GRS consisted only of male subjects. It would be interesting to investigate this GRS in women, too, still considering the same cohort study design and population. Transferring this "male GRS" into women in the clinical environment may not lead to a similar predictive performance. Therefore, such male-specific GRS should be treated carefully if no GRS exists for women, and a generalization for the entire population would not be recommended. Thus, in general, there are still difficulties in transferring results from genetic analyses across populations, which, however, would be necessary for a broader clinical utilization of the genetic information.
The selection of the genetic variants to be included in the GRS is another matter of debate. Should SNPs from biologically plausible candidate gene studies be included or SNPs found to be associated with traits through GWAS from large consortia efforts? To which threshold (genomewide significance or up to thousands of the "top" SNPs) should the associated SNPs be included? Typically, consortium-based meta-analyses also include a replication phase, which further enhances the robustness of the findings. On the contrary, because meta-analyses tend to lack sufficient power to detect effects from rarer variants, the vast majority of GRSs include only common variants [11] with possible smaller effect sizes. The GRS used in the current study [7] was based on a combination of SNPs identified by GWAS and candidate gene studies [8] . Furthermore, the selection of several thousands of SNPs in a GRS might have the potential to reflect more accurately the biological basis of the genetic associations.
In addition, technical challenges have to be tackled before suggesting a novel GRS. To reach clinically meaningful results for risk prediction, adequate clinical phenotyping and design of prospective studies as well as a harmonized and automatized processing, data acquisition and statistical analysis procedures are mandatory. Genotyping in the current study [7] was performed at different times and by different methods: some SNPs had been genotyped using restriction length polymorphism methods and some were genotyped using TaqMan and KASPar assays. This needs to be viewed critically, as different methods do not always show the same efficacy and might inaccurately measure the genotype, leading to false results. This might also be an explanation as to why the newly 21-SNP GRS assessed by Beaney et al. [7] showed poor calibration and no improvement over the QRISK2 after exchange of 7-SNPs compared to the 19-SNP GRS.
In the future, further loci will be identified and improved and new risk prediction algorithms may even be available. These advantages come along with further challenges, e.g. for the selection of "the most" suitable genetic variants to be incorporated in GRSs and the subsequent interpretation and utility of the associations.
In aggregate, the value of combining risk factors with genetic predisposition, as shown by several studies, has been confirmed by the work of Beaney et al. [7] . However, the impact of GRS on clinical decision-making is still unclear and current results from population cohorts ultimately, need to be tested in controlled clinical trials. As genetic testing has become widely available and as the cost of determining genetic information drops, it is worth further examining the value of genetics incorporated into the prognostic evaluation and treatment of cardiovascular disease.
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